Scientific Industries Inc

and welcome to the Scientific Industries Reports third quarter fiscal year 2025 financial results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touch-tone phone. To withdraw your question, please press star, then two. Please note this event is being recorded. I would now like to turn the conference over to Joe Dorme, Managing Partner. Please go ahead.

Thanks, Bailey. Good morning, and thank you for joining us today to review Scientific Industries' financial results for the third quarter of 2025, ended September 30, 2025. With us today on the call are Helena Santos, Chief Executive Officer, Daniel Donadie, CEO of SBI, and John Moore, Chairman. After the conclusion of today's prepared remarks, we'll open the call for questions. Before we begin with prepared remarks, I would like to remind everyone, certain statements made by the management team of scientific industries during this conference call constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Except for the statements of historical fact, this conference call may contain forward-looking statements that involve risks and uncertainties, some of which are detailed under risk factors and documents filed by the company with the Securities and Exchange Commission, including the annual report on Form 10-K for the year end of December 31, 2024. Forward-looking statements speak only as of the date the statements were made. The company can give no assurance that such forward-looking statements will prove to be correct. Scientific Industries does not undertake and specifically disclaims any obligation to update any forward-looking statements except as required by law. Now I'd like to turn it over to Helena Santos, CEO of Scientific Industries. Helena?

Thank you so much, Joe, and thank you for joining us today. This quarter, and indeed this year, marked a pivotal moment in our company's journey. As highlighted in our previous earnings call, we closed a significant chapter after 70 years with the divestiture of our legacy Genie products division. This happened in mid-August. Since then, our team has been fully focused on ensuring a smooth transition to the buyer for all aspects of the Genie product line. What does this mean? This means that we are assisting them with the transition of the production, the engineering, customers, and suppliers. We expect to complete the process and, most importantly, secure the final installment of the sale price over the next three to six months, depending on how they move. Turning to our benchtop lat equipment operations, we remain committed to building value in our Torval division. To this end, we're actively pursuing new growth opportunities with our legacy scales and continuing to innovate across our Vivid bill counter portfolio. This quarter, very recently actually, we introduced an exciting new AI-driven feature to our Vivid workstation. This enhancement offers customers actionable insights. It strengthens regulatory compliance for them and delivers meaningful cost savings as well. It's just the first of several strategic improvements that we have planned in order to position the Vivid as the premier pill counting solution in the market. On the bioprocessing front, our team is focused on completing the DOTS platform and refining its core components that have been already introduced into the marketplace. Mr. Donadio will share further details in just a few moments. As we approach the end of the year, we acknowledge the challenges, particularly in the bioprocessing sector, as Mr. Donadio will go into. But we remain confident in our direction. I believe that the decisive actions we've taken during the year and our relentless pursuit of innovation have set us on the right path for sustainable growth. I thank you for your continued trust and partnership, particularly with our valued shareholders. With that, I'll hand things over to Daniel Donadio for more on our financial and operational progress of the bioprocessing segment. Daniel?